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ABSTRAK 
 
 
 
 
Akut mieloid leukemia (AML) dengan t (8,21) translocation adalah salah satu kelainan 
karyotypic yang paling kerap diperhatikan dalam AML yang menghasilkan gen bergabung 
onko-protein, AML1/ETO. siRNA adalah alat penggangguan RNA (RNAi) yang biasa 
digunakan untuk mendorong pembubaran jangka pendek gen pengekodan protein. Terdapat 
kajian menunjukkan bahawa pembubaran AML1/ETO akan menaikkan atau mengurangkan 
regulasi dalam pelbagai gen yang bertanggungjawab untuk apoptosis, percambahan, dan 
pembaharuan diri sel. FOXO3 bertindak sebagai gen penindas tumor melalui pencetusan 
apoptosis dengan menaikkan regulasi sementara c-MYC adalah proto-onkogene yang 
didapati dinaikkan regulasi dalam banyak jenis kanser. Walau bagaimanapun, hubungan 
antara ketiga-tiga gen ini tidak diketahui. Oleh itu, objektif kajian ini adalah untuk mengkaji 
supresi gen AML1/ETO melalui kaedah perencatan gen dengan menggunakan siRNA dan 
kesannya terhadap ekspresi gen FOXO3 dan c-MYC dalam sel-sel t (8,21) Kasumi-1. Ia telah 
dihipotesiskan bahawa kaedah perencatan gen menggunakan siRNA adalah cekap dalam 
supres gen AML1/ETO dan terdapat korelasi antara gen AML1/ETO, FOXO3 dan c-MYC. 
Hipotesis ini diuji secara eksperimen menggunakan perencatan gen AML1/ETO melaui 
electroporasi siRNA diikuti oleh kajian tahap ekspresi gen FOXO3 dan c-MYC menggunakan 
qPCR. Hasil daripada siRNA yang diantarkan eksperimen supresi AML1/ETO dengan 
xv 
 
menggunakan siAGF1 menunjukkan bahawa terdapat penurunan sebanyak 52% pada 24 jam 
(p=0.005), 65% (p=0.002) pada 48 jam dan 85% (p=0.018) pada 72 jam. Sedangkan 
keputusan tahap ekspresi gen FOXO3 dikurangkan sebanyak 3% pada 24 jam (p=0.860), 48 
jam menunjukkan 50% peningkatan (p=0.153) dan 72 jam menunjukkan 46% (p=0.154). 
Ekspresi c-MYC meningkat 11% pada 24 jam (p=0.821), 48 jam menunjukkan 83% 
meningkat (p=0.232) manakala 72 jam menunjukkan 25% penurunan ekspresi (p=0.209). 
Keputusan ekspresi gen setelah perencatan gen tidak menunjukkan korelasi konklusif atau 
signifikan antara AML1/ETO, FOXO3 dan c-MYC. Perencatan gen berpanjangan disarankan 
untuk mengesahkan lagi hasil carian. 
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SUPPRESSION OF AML1/ETO VIA siRNA MEDIATED GENE KNOCKDOWN 
AND ITS EFFECTS ON FOXO3 AND c-MYC EXPRESSION IN AML t (8,21) 
CELLS 
 
 
 
 
ABSTRACT 
Acute Myeloid Leukemia (AML) with t (8,21) translocation is one of the most frequent 
karyotypic abnormalities observed in AML that results in formation of fusion onco-protein, 
AML1/ETO. siRNA is a commonly used RNA interference (RNAi) tool to induce short-term 
silencing of protein coding genes. There are studies shows that silencing of AML1/ETO 
results in up- or down-regulation of various gene responsible for apoptosis, proliferation, and 
self-renewal of cells. FOXO3 act as a tumor suppressor gene by triggering apoptosis with its 
upregulation while c-MYC is a proto-oncogene which is found to be upregulated in many 
types of cancers. Nonetheless, the correlation between these three genes is not known. 
Therefore, the objective of this study was to study the suppression of AML1/ETO gene via 
siRNA mediated knockdown and its effect on FOXO3 and c-MYC gene expression in AML 
t (8,21) positive Kasumi-1 cell. It was hypothesized that siRNA mediated knockdown is 
efficient in suppressing AML1/ETO gene and there is a correlation between AML1/ETO, 
FOXO3 and c-MYC gene. This hypothesis was experimentally tested using a siRNA 
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mediated gene knockdown by electroporation of AML1/ETO followed by the study of gene 
expression level of FOXO3 and c-MYC using qPCR. The result of siRNA mediated 
AML1/ETO gene knockdown experiments using siAGF1 reveal that there is a knockdown of 
52% at 24 hours (p=0.005), 65% (p=0.002) at 48 hours and 85% (p=0.018) at 72 hours. 
Whereas the result of gene expression level of FOXO3 reduced by 3 % at 24 hours (p=0.860), 
48 hours showed a 50% of increase (p=0.153) and 72 hours showed a 46% (p=0.154) of 
decrease in expression.  Expression of c-MYC increased by 11% at 24 hours (p=0.821), 48 
hours showed 83% of increased (p=0.232) while 72 hours showed 25% of decreased in 
expression (p=0.209). The results of gene expression after gene knockdown does not show 
conclusive or significant correlation between AML1/ETO, FOXO3 and c-MYC which a 
prolong knockdown is suggested to further verify the finding.
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CHAPTER 1 INTRODUCTION 
Leukemia is a disease involving bone marrow and blood which consists of four types of 
leukemia namely Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia 
(CLL), Acute Lymphoblastic Leukemia (ALL) as well as Acute Myeloid Leukemia (AML). 
Among the four types of leukemia, The most commonly occur acute leukemia among adults 
is AML and the occurrence will increase with age (Deschler and Lubbert, 2006). 
As stated by French-American-British (FAB) classification, t (8,21) (q22; q22) is the most 
general karyotypic abnormalities encounter in M2 subtype of AML (LeBeau and Rowley, 
1984). Runt-related transcription factor RUNX1/AML1 which is a key regulator that involve 
in process of hematopoiesis is the most common target of chromosomal translocations occur 
in Acute Myeloid Leukemia. During the translocation, AML1 gene located at chromosome 
21 will fuses with ETO gene which is located at chromosome 8 resulting in the construction 
of AML1/ETO fusion protein (Sweetser et al., 2005). 
 Sweetser et al,. at 2005 suggest that cells which loss the expression of AML1/ETO will 
caused the increased in proliferation and cell survival thus giving a good prognosis for AML 
patients (Sweetser et al., 2005). However, AML1/ETO gene singly may be insufficient to 
induce leukemia (Rhoades et al., 2000) . There is a lack of study regarding the roles of 
AML1/ETO involve in process of inducing leukemogenesis (Heidenreich et al., 2003) . 
According to Heidenreich et al., 2003, an approach which is through the selective depletion 
of AML1/ETO gene in leukemic cells can give a rough idea on the role of the gene and it can 
also study the effects of AML1/ETO depletion on gene expression (Heidenreich et al., 2003) . 
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A study by Spirin et al., in 2014 that used RNA-interference (RNAi) specifically short hairpin 
RNA (shRNA) as a method for explanation regarding the functional consequences on the 
suppression of AML1/ETO in AML t (8,21) Kasumi-1 cell line shows a notable decrease in 
expression of KIT accompanied by growth inhibition and increase in apoptosis of the 
leukemic cells (Spirin et al., 2014).  
FOXO transcription factors functions in regulation of growth, cells differentiation, cells 
survival, stress, cell cycle, metabolism, and tumor suppression pathways. The function of 
FOXO factors involve in development of tumor was primarily proposed through studies that 
three of the FOXO genes were found at chromosomal breakpoints in various category of 
cancer which are rhabdomyosarcomas for FOXO1, and Acute Myeloid Leukemia for FOXO3 
and FOXO4 (Barr, 2001).  
While in some studies, FOXO3 was found to be removed in carcinogen-induced human lung 
adenocarcinoma (LAC) of mice and in human non-small cell lung cancer (NSCLC) cell lines. 
The findings from this study show that the loss of FOXO3 causes the pathogenesis of NSCLC 
(Herzog et al., 2009, Blake et al.). FOXO3 gene was recognize as one of the novel target for 
deletion in human lung adenocarcinoma. Homozygous or bi-allelic removal of  FOXO3 was 
identified mostly in early-stage LAC among smokers which made up of 24.2% (Mikse et al., 
2010). Inactivation of FOXOs occurs in most of human cancers, due to over activation of 
PI3K/Akt pathway and the latter is caused by mutations that occur in RAS, PTEN or PI3K 
(Dansen and Burgering, 2008). These studies suggest that FOXOs can act as a tumor 
suppressors factor that may be use as therapeutic purposes (Jin et al., 2004). 
Posttranslational modifications (PTMs) play a crucial part in regulating the activity of FOXO 
transcription factors which resulting in changes of the subcellular localization of these 
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proteins (Brunet et al., 1999) . Based on a study by Chapuis et al., on 2010 the importance of 
PTMs on FOXO3 activity and the involvement of FOXO3 in tumor-associated chromosomal 
aberrations in AML had assumed that the loss of FOXO3 tumor suppressive function may 
represent a common feature in AML cells and could contribute to leukemogenesis. The 
killing of leukemic cells can be induced through restoring of FOXO3 tumor suppressive 
functions and could thus represent an attractive perspective in AML therapy (Chapuis et al., 
2010). 
The c-MYC gene has appear as central oncogenic switch in various types of cancers. The 
discovery that human cancers that often show altered expression of  human c-MYC gene had 
drawn attention to the importance on the function of this gene in development of human 
cancers (Evan et al., 1992). The ability of c-MYC protein as a transcription factors that are 
able to regulate gene expression both positively and negatively plays a major part in cell 
growth and proliferation (Adhikary and Eilers, 2005, Eilers and Eisenman, 2008). The most 
common events related with cancer are the amplification, mutation, or activation of MYC 
oncogene family (Eilers and Eisenman, 2008). In AML, activation of the c-MYC gene is 
commonly occur and the activation has play a major part in triggering the event of leukemia 
(Hoffman et al., 2002, Renneville et al., 2008). 
RNAi has been proven to be a very useful research tool that allows a much more rapid 
characterization on the function of certain known genes (Mocellin and Provenzano, 2004). 
Currently, RNA interference is a popular method in gene silencing or gene knockdown where 
it is easy to perform, relatively nontoxic, affordable, and it is highly specific. RNA 
interference (RNAi) which consists of siRNA, miRNA and shRNA has known as a natural 
mechanism for gene expression silencing over the past decades. siRNA technology is 
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successfully used in genomic studies to study between the genes functions and their 
interaction, and also serve as a method in discovery for new pharmaceutical preparations 
(Rulina et al., 2010). RNA interference is a promising option as a base for new biomedical 
approach against different diseases which also include tumors (Rulina et al., 2010). 
 However, RNAi has its own limitations despite the facts that significant efforts have been 
made as compared to previous practice done. Not all sequence can achieve its target, with 
most of the researchers only reports about one in three of a success rate. In addition, although 
the effects of RNAi are generally assumed to be highly sequence-specific, there are some 
doubts that still remain as to whether some of the effects observed are "off target"(Mocellin 
and Provenzano, 2004).  
As all three AML1/ETO, FOXO3 and c-MYC plays a role in affecting Acute Myeloid 
Leukemia individually, however, there is a lack of study in understanding the correlation 
between these three genes during the process of leukemogenesis in Acute Myeloid Leukemia. 
Therefore, a study on the relationship between AML1/ETO, FOXO3 and c-MYC can be an 
interesting knowledge gap to fill.  Besides that, this study also aims to experiment on the 
efficiency of siRNA in suppressing AML1/ETO gene.  
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1.1 Problem Statement: 
AML1/ETO, FOXO3 and c-MYC genes are involved in the progression of cancer respectively, 
however the correlation between these three genes in AML are not well established. Hence, 
the study serves to explore the association between AML1/ETO, FOXO3 and c-MYC genes 
in AML cells. 
 
1.2 Objectives: 
1.2.1 General objective: 
To study the expression among AML1/ETO, FOXO3 and c-MYC genes in AML t (8,21) cells  
1.2.2 Specific objectives: 
i) To suppress AML1/ETO gene in Kasumi-1 cell line using siRNA 
ii) To measure the gene expression level of FOXO3 and c-MYC after suppression of 
AML1/ETO in Kasumi-1 cells using Real Time PCR 
 
1.3 Hypothesis 
1.3.1 Hypothesis 1: 
siRNA is efficient in suppressing AML1/ETO gene in AML t (8,21) cells. 
1.3.2 Hypothesis 2: 
There is correlation between AML1/ETO, FOXO3 and c-MYC genes in AML t (8,21) cells.  
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CHAPTER 2 LITERATURE REVIEW 
2.1 Acute Myeloid Leukemia (AML) 
Leukemia is one of the well-known oncological disease that is distinguished by an increased 
in morphologically immature blood cells which are known as blasts, where the blast cells are 
unable to perform normal functions of mature cells and instead it will exclude normal 
precursors because of the active proliferation (Rulina et al., 2010). In clinical definition, 
leukemias that start acutely and display rapid progression are known as acute leukemias. 
Delayed in or lack of treatment will cause death within a few months’ time. Acute leukemia 
is a form of heterogenous group of malignant diseases of the hematopoietic system 
characterized by the existence of large number of blast cells in blood of the patient which 
will cause specific damage to the blood marrow (Rulina et al., 2010).  
AML is one of the cancerous disease of blood which commonly occur among the adults that 
arise from the transformation and differentiation of hematopoietic cells of the myeloid cell 
lines (Rubnitz et al., 2008). AML can be distinguished by a rise in  numbers of myeloid cells 
in bone marrow and halt in the progression of the precursor cells which usually results in 
insufficiency of hematopoietic cells such as thrombocytopenia, anemia or granulocytopenia, 
with or without the occurrence of leukocytosis (Lowenberg et al., 1999). In the absence of 
treatment within one year, the failure of myeloid precursor cells to differentiate will lead to 
fatal infection, bleeding or organ infiltration (Estey and Döhner, 2006). 
AML patients with cytogenetic abnormalities of t (8,21) will present with specific biological 
and clinical characteristics and the criteria of diagnosis varies from different AML patients 
where the biological features that the leukemia showed are atypical in other AML subtype 
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and the prognosis after an intensive chemotherapy shows significant improvement in these 
patients compared to the majority of AML patients (Campo et al., 2011).  
 
2.1.1 AML Classification 
Two different classification systems that are frequently used in staging Acute Myeloid 
Leukemia which are the French-American-British (FAB) classification system (Table 2.1) 
that define a specific immunotypes based on the cells morphology observed and the World 
Health Organization (WHO) classification system(Table 2.2) that analyze the chromosome 
translocation and evidence of dysplasia (Rulina et al., 2010).  
In FAB classifications, AML is subdivides into eight different subclasses which is M0-M7 
and the patients will have different prognoses and receive different treatment depending on 
the subclasses (Bennett et al., 1976). While WHO classification of AML was established take 
into consideration of the FAB system. WHO classification is more conveniently use for 
clinical application because it take into account the most significant prognostic signs of the 
disease found in AML (Vardiman et al., 2002).  
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Table 2.1. French-American-British (FAB) classification of AML. (Tenen, 2003) 
FAB 
subtype 
Description Comments 
M0 Undifferentiated Myeloperoxidase negative; myeloid marker 
positive  
M1 Myeloblastic without maturation Some evidence of granulocytic differentiation 
M2 Myeloblastic with maturation Maturation at or beyond the promyelocytic 
stage of differentiation; can be divided into 
those with t (8,21) AML1-ETO fusion and those 
without 
M3 Promyelocytic APL; most cases have t (5,17) PML-RARα or 
another translocation involving RARα 
M4 Myelomonocytic  
M4EO Myelomonocytic with bone-marrow 
eosinophilia 
Characterized by inversion of chromosome 16 
involving CBFβ, which normally forms a 
heterodimer with AML1 
M5 Monocytic  
M6 Erythroleukaemia  
M7 Megakaryoblastic GATA1 mutations in those associated with 
Down’s syndrome 
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Table 2.2. WHO classification of Acute Myeloid Leukemia. (Arber et al., 2016) 
Acute myeloid leukemia (AML) and related neoplasms 
AML with recurrent genetic abnormalities 
    AML with t (8,21) (q22; q22.1); RUX1-RUNX1T1 
    AML with inv (16) (p13.1q22) or t (16;16) (p13.1; q22); CBFB-MYH11 
    AML with PML-RARA 
    AML with t (9,11) (p21.3; q23.3); MLLT3-KMT2A 
    AML with t (6;9) (p23; q34.1); DEK-NUP214 
    AML with inv (3) (q21.3q26.2) or t (3;3) (q21.3; q26.2); GATA2, MECOM 
    AML (megakaryoblastic) with t (1;22) (p13.3; q13.3); RBM15-MKL1 
    Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
AML, NOS  
    AML with minimal differentiation 
    AML without maturation 
    AML with maturation 
    AML myelomonocytic leukemia 
    Acute monoblastic/monocytic leukemia 
    Pure erythroid leukemia 
    Acute megakaryoblastic leukemia 
    Acute basophilic leukemia 
    Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
    Transient abnormal myelopoiesis (TAM) 
    Myeloid leukemia associated with Down syndrome 
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2.1.2 Clinical and Hematological Characterization of AML 
The appearance and development of leukemias during the initial stage is generally 
asymptomatic. Usually, the patients will feel themselves in good health until the spread of 
cancer cells occur throughout the hematopoietic system. Acute leukemia can be diagnosed 
through morphological examination of bone marrow or peripheral blood of patient for 
presence of blast tumor cells. The morphology of AML cells in bone marrow and peripheral 
blood shown in Figure 2.1 is characterized by large myeloblasts with plenty of basophilic 
cytoplasm and often containing azurophilic granules. Replacing normal hematopoietic stem 
cells with neoplastic cells will cause a decrease in range of blood cells such as anemia, 
thrombocytopenia, and neutropenia, the replacement will also leads to the manifestation of 
frequent infectious disease and mucosal ulcerations (Vorob’ev and Lorie, 2002). 
In acute myeloid leukemia, presence of blast cells and a “leukemic gap’’ can be seen in the 
peripheral blood leukocytosis. The ‘’leukemic gap’’ is characterized by a drastic elevation in 
the number of blast cells and unique mature elements that exist along with the lack of 
transitional maturing forms.  While in few cases of AML, the leukocyte number will remain 
the same but the blast cells will consistently present and if the blast cells are incapable of 
leaving the bone marrow, the number of blast cells will be rather high (Vorob’ev and Lorie, 
2002). According to Rubnitz et al., on 2008, AML can be diagnosed depend on the existence 
of over 30% of myeloblasts present in the bone marrow (Rubnitz et al., 2008). 
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Figure 2.1. Acute Myeloid Leukemia with t (8,21) (q22; q22). Bone marrow blasts showing 
abundant granular cytoplasm with perinuclear clearing and large orange-pink granules. 
(1000x magnification) 
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2.1.3 Molecular Genetics of AML t (8,21) 
Separation of cooperating mutations of different genes that results in the manifestation of 
AML will increase the cells proliferative ability and survival which have an impact on the 
normal differentiation and apoptosis process of cells precursors that incudes myeloid, 
erythroid, megakaryocytic and also monocytic lineage. Acute leukemias are made up of 
clonal cell line that arise from either a partially differentiated or a very early cell precursor 
towards different hematopoietic series in a single mutant hematopoietic cell. The clinical 
course of acute leukemia, therapy programs and its effectiveness can be determine through 
the relation between a definite hematopoietic series of blast cells and their level of 
differentiation (Grimwade et al., 1998). 
Among the types of mutations involve in AML, Class II mutations are the mutations that 
affect the genes of transcription factors and cause alterations in the functions or activity of 
the genes and affects cell differentiation. The most frequent class II mutation that occurs in 
AML is the translocation of t (8;21) (q22; q22) and inversion (16) (p13; q22) and this 
translocation results in the formation of fused proteins AML1-ETO and CBFβ/MYH11 on 
the functional level (Wakita et al., 2011). Class II mutation is inadequate for cancer 
transformation therefore class I mutations which is a secondary genetic rearrangement is 
required to obtain the tumor phenotype. Class I mutation happens in the tyrosine kinases gene 
which cause the essential activation and thus cell proliferation and cell survival. Among the 
tyrosine kinases genes, tyrosine kinases KIT and FLT3 genes are the genes that the AML 
mutations most commonly occur (Kelly and Gilliland, 2002).  
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2.1.4 Epidemiology of AML in Malaysia 
According to forecast made by the World Health Organization (WHO), oncologic diseases 
may surpass cardiovascular diseases and become the leading killer disease in near future 
(Rulina et al., 2010). Cancer has become one of the major cause of death in Malaysia 
nowadays. As reported by the Malaysian National Cancer Registry Report (MNCR), there 
are a total of 103,507 new cancer cases were diagnosed in Malaysia during the duration of 
2007 to 2011, of which 46,794 or 45.2% were reported in males and 56, 713 or 54.8% were 
reported in females. As per the report, the chances of males getting cancer was 1 in 10 while 
there is a risk of 1 in 9 for females.  
Among the cancers reported shown in Table 2.3, from 2007 to 2011 leukemia is the sixth 
most common cancers occur in Malaysia population with the number of 4, 573 out of total 
cases of 103,507 or 4.4% of which 2, 549 or 5.4% were reported in males and 2, 024 or 3.65% 
were reported in females. It is the most common cancer among 0-14 years old with Malay 
had the highest rate followed by Chinese and Indian in both sexes. The lifetime risk for males 
was 1 in 275 and 1 in 348 for females.  
According to the data collected by the Malaysian National Cancer Registry, AML is 
commonly occurring among elderly people as compared to other types of leukemia and as 
shown in Figure 2.2 and Figure 2.3, the average age of incidence of AML among females 
and males are between 60 to 75 years old. The statistical data also showed that AML is more 
commonly occur in males compare to females with males has a prevalence rate of 7 cases in 
every 100,000 people while females has a prevalence rate of 6 cases in every 100,000 people 
in population. 
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Table 2.3 Ten most common cancers in Malaysia population. (Adapted from Malaysian 
National Cancer Registry Report (MNCR) 2007-2011). 
ICD-10 Sites Number % 
C50 Breast 18,343 17.7 
C18-C21 Colorectal 13,693 13.2 
C33-C34 Trachea, Bronchus, Lung 10,608 10.2 
C81-C85, C96 Lymphoma 5,374 5.2 
C11 Nasopharynx 5,090 4.9 
C91-C95 Leukemia 4,573 4.4 
C53 Cervix Uteri 4,352 4.2 
C22 Liver 4,128 4.0 
C56 Ovary 3,472 3.4 
C16 Stomach 3,461 3.3 
 Others 30,413 29.4 
 Total 103,507 100.0 
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Figure 2.2 Leukemia types: Age-specific incidence rate, females, Malaysia, 2007-
2011(Adapted from Malaysian National Cancer Registry Report (MNCR) 2007-2011).  
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Figure 2.3 Leukemia types: Age-specific incidence rate, males, Malaysia, 2007-
2011(Adapted from Malaysian National Cancer Registry Report (MNCR) 2007-2011). 
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2.2 AML1/ETO Gene 
There are around 40% of M2 AML cases is associated with t (8,21) karyotypic abnormalities 
(Bitter et al., 1987) and this translocation has the most frequent chromosomal anomaly that 
can be found in 18-20% of leukemia cases (Look, 1997, Mitelman and Heim, 1992). The 
combination of AML1 gene that located at chromosome 21q22 with ETO gene located at 
chromosome 8q22 results in formation of AML1/ETO chimeric protein as shown in Figure 
2.4 which carries a transcriptional activity (Rulina et al., 2010).  This fusion protein of 
AML1-ETO encodes an initial 177 of AML1 amino acids that links to the ETO sequences 
(Erickson et al., 1992, Miyoshi et al., 1991). AML1/ETO is identify in blood and also in 
marrow sample of AML patient who achieve long-term complete remissions after treated 
with chemotherapy or hematopoietic stem cell transplantation (Miyamoto et al., 1995).  
AML1/ETO fusion protein solely is inadequate in causing leukemia, however the 
downregulation in the expression of enzyme 8- oxoguanine DNA glycosylase (OGG1) which 
is  involved in the DNA repair might cause the addition of genetic abnormalities that leads 
to development of AML (Liddiard et al., 2010). There are some experimental and clinical 
studies that draw attention to the importance of secondary mutations in AML1-ETO that 
mediates the development of leukemia. For instance, expression of AML1/ETO gene in mice 
will require an exposure to mutagen such as N-ethyl-N-nitrosourea or through a co-
expression of constitutively active tyrosine such as TEL-PDGFRβ fusion for the 
development of AML (Higuchi et al., 2002, Grisolano et al., 2003).  
Similarly, the clinical data also show high prevalence of secondary genetic alteration that 
will affects the tyrosine kinase signal transduction pathways in AML patient present with t 
(8,21) translocation. Based on the observation done by Wang et al., in 2005, approximately 
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50% of the involved AML patients that present with t (8,21) had point mutations in the  
tyrosine kinase gene C-KIT receptor (Wang et al., 2005). The hyperexpression of tyrosine 
kinase KIT receptor only occur in approximately 5% of AML patient but with the presence 
of AML1/ETO which results from the t(8,21) translocation frequency of mutation has shown 
an increased up to 30% (Peterson and Zhang, 2004) . The association between the two 
oncogenes was known for a certain of time. It was assumed that the presence of two activated 
oncogenes in cells for example transcription factor AML1-ETO and tyrosine kinase c-kit will 
function to promote their malignization. 
Besides that, Wang et al., also discovered that majority of leukemia with t (8,21) 
translocation are more likely to overexpress c-Kit despite the mutational status. While in 
other study by Schessl et al., at the same year of 2005 found that more than one third of AML 
patient with t (8,21) translocation to conceal activated mutations in either FLT3, C-KIT or 
NRAS (Schessl et al., 2005). Furthermore, the study also showed AML1/ETO will cooperate 
with mutated FLT3 to trigger the development of leukemia in transplanted mice and this 
emphasizes the importance of cooperation between expression of AML1/ETO and abnormal 
tyrosine kinase signaling in the development of leukemia (Schessl et al., 2005). 
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Figure 2.4. Translocation of t (8,21) (q22; q22) resulting in formation of fused gene 
AML1/ETO. (Modified from Rulina et al., 2010). 
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2.2.1 Classical Model of Leukemogenesis by AML1/ETO 
In a corresponding model, RUNX 1 will commonly functioned as transcriptional activator 
that upregulate target genes from specific lineage such as myeloperoxidase to promotes 
differentiation of granulocytes. RUNX1 will go through a metamorphosis process of 
switching from activator to suppressor which will downregulate all of the target genes that 
involved in differentiation of cells from granulocytic lineage through the combination of 
RUNX 1 with ETO which result from the t (8,21) translocation. (Elagib and Goldfarb, 2007) 
 
2.3 A Model Cell Line for AML t (8,21)  
The Kasumi-1 cells is a human cells line that was obtained from peripheral blood sample of 
a 7-year old Japanese boy present with AML that has relapsed after a bone marrow transplant. 
The Japanese boy was diagnosed with M2 subtype AML at Matsuyama Red Cross Hospital 
(Matsuyama, Japan). The first incident of leukemia relapsed occurred after a complete 
remission that was achieved through chemotherapy. On the following relapsed, a bone 
marrow transplant was done on this boy at Hiroshima Red Cross Hospital (Hiroshima, Japan) 
collected from his HLA-matched sibling at the second complete remission after introduced 
by mitxantrone and cytosine arabinoside. The relapsed occurred 98 days after the 
transplantation where the engraftment was achieved and further application of chemotherapy 
failed. The patient died due to disease progression.  
During the whole clinical course, there was no leukemic cells with cancer formation observed 
outside the marrow cavity. The blood sample was collected when the patient’s leukocyte 
count was 99,800/µL with 93% blasts using a heparinized syringe. The Kasumi-1 cells were 
